WHat is Ocular graft-versus-host-disease?

---

Graft-versus-host-disease (GVHD) is a common condition that occurs after allogenic stem cell transplants that can cause symptoms such as skin rashes, nausea, vomiting, diarrhea, dry eyes, and other related conditions. A specific form of GVHD called Ocular GVHD (oGVHD) develops in "approximately 40-60% of patients" following a stem cell transplant and can lead to severe ocular surface disease which can diminish the patient's quality of life and restrict daily activities (Nassiri et al, 2013). 

Currently, the only treatment given to patients that present with oGVHD is artificial tears. Although effective in relieving symptoms in the short term, long term symptoms such as redness, pain, and irritation remain. This study aims to determine if medicated eye drops will be effective in reducing oGVHD symptoms. 

Yes, the study is safe. The drug we will be using is FDA approved for ocular use in dry eye patients. The study goal is to determine if it helps this more targeted population. As these patients tend to suffer greatly from dry eye symptoms, it could be highly beneficial for them to be a part of this study.